Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups. Read More ›

Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low. Read More ›

CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation. Read More ›

In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment. Read More ›

Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans. Read More ›

A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated. Read More ›

Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer. Read More ›

Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy. Read More ›

Next-generation sequencing at initial workup of the patient with advanced non–small-cell lung cancer can shorten time between diagnosis and treatment and may improve survival. Read More ›

Recent study found that the use of sotorasib after anti–PD-L1 therapy in patients with NSCLC increased the chance of severe adverse events and liver toxicity. Read More ›